Literature DB >> 22157624

New immune therapy targets tumor-associated environment: from bone marrow to tumor site.

Yang-Xin Fu.   

Abstract

Entities:  

Mesh：

Year:  2011        PMID： 22157624      PMCID： PMC4002937          DOI： 10.1038/cmi.2011.54

Source DB:  PubMed          Journal:  Cell Mol Immunol        ISSN： 1672-7681            Impact factor:   11.530


× No keyword cloud information.
  21 in total

1.  Anti-ErbB-2 mAb therapy requires type I and II interferons and synergizes with anti-PD-1 or anti-CD137 mAb therapy.

Authors:  John Stagg; Sherene Loi; Upulie Divisekera; Shin Foong Ngiow; Helene Duret; Hideo Yagita; Michele W Teng; Mark J Smyth
Journal:  Proc Natl Acad Sci U S A       Date:  2011-04-11       Impact factor: 11.205

2.  Recruitment and activation of naive T cells in the islets by lymphotoxin beta receptor-dependent tertiary lymphoid structure.

Authors:  Youjin Lee; Robert K Chin; Peter Christiansen; Yonglian Sun; Alexei V Tumanov; Jing Wang; Alexander V Chervonsky; Yang-Xin Fu
Journal:  Immunity       Date:  2006-08-24       Impact factor: 31.745

Review 3.  Immunosuppressive networks in the tumour environment and their therapeutic relevance.

Authors:  Weiping Zou
Journal:  Nat Rev Cancer       Date:  2005-04       Impact factor: 60.716

4.  The therapeutic effect of anti-HER2/neu antibody depends on both innate and adaptive immunity.

Authors:  SaeGwang Park; Zhujun Jiang; Eric D Mortenson; Liufu Deng; Olga Radkevich-Brown; Xuanming Yang; Husain Sattar; Yang Wang; Nicholas K Brown; Mark Greene; Yang Liu; Jie Tang; Shengdian Wang; Yang-Xin Fu
Journal:  Cancer Cell       Date:  2010-08-09       Impact factor: 31.743

5.  Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival.

Authors:  Tyler J Curiel; George Coukos; Linhua Zou; Xavier Alvarez; Pui Cheng; Peter Mottram; Melina Evdemon-Hogan; Jose R Conejo-Garcia; Lin Zhang; Matthew Burow; Yun Zhu; Shuang Wei; Ilona Kryczek; Ben Daniel; Alan Gordon; Leann Myers; Andrew Lackner; Mary L Disis; Keith L Knutson; Lieping Chen; Weiping Zou
Journal:  Nat Med       Date:  2004-08-22       Impact factor: 53.440

6.  Cancer immunotherapy: moving beyond current vaccines.

Authors:  Steven A Rosenberg; James C Yang; Nicholas P Restifo
Journal:  Nat Med       Date:  2004-09       Impact factor: 53.440

7.  Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy.

Authors:  Lionel Apetoh; François Ghiringhelli; Antoine Tesniere; Michel Obeid; Carla Ortiz; Alfredo Criollo; Grégoire Mignot; M Chiara Maiuri; Evelyn Ullrich; Patrick Saulnier; Huan Yang; Sebastian Amigorena; Bernard Ryffel; Franck J Barrat; Paul Saftig; Francis Levi; Rosette Lidereau; Catherine Nogues; Jean-Paul Mira; Agnès Chompret; Virginie Joulin; Françoise Clavel-Chapelon; Jean Bourhis; Fabrice André; Suzette Delaloge; Thomas Tursz; Guido Kroemer; Laurence Zitvogel
Journal:  Nat Med       Date:  2007-08-19       Impact factor: 53.440

8.  Targeting lymphotoxin-mediated negative selection to prevent prostate cancer in mice with genetic predisposition.

Authors:  Penghui Zhou; Xianfeng Fang; Beth A McNally; Ping Yu; Mingzhao Zhu; Yang-Xin Fu; Lizhong Wang; Yang Liu; Pan Zheng
Journal:  Proc Natl Acad Sci U S A       Date:  2009-09-23       Impact factor: 11.205

9.  Bone marrow is a reservoir for CD4+CD25+ regulatory T cells that traffic through CXCL12/CXCR4 signals.

Authors:  Linhua Zou; Brian Barnett; Hana Safah; Vincent F Larussa; Melina Evdemon-Hogan; Peter Mottram; Shuang Wei; Odile David; Tyler J Curiel; Weiping Zou
Journal:  Cancer Res       Date:  2004-11-15       Impact factor: 12.701

10.  Intratumor depletion of CD4+ cells unmasks tumor immunogenicity leading to the rejection of late-stage tumors.

Authors:  Ping Yu; Youjin Lee; Wenhua Liu; Thomas Krausz; Anita Chong; Hans Schreiber; Yang-Xin Fu
Journal:  J Exp Med       Date:  2005-03-07       Impact factor: 14.307
View more
  4 in total

Review 1.  NK cell receptor imbalance and NK cell dysfunction in HBV infection and hepatocellular carcinoma.

Authors:  Cheng Sun; Haoyu Sun; Cai Zhang; Zhigang Tian
Journal:  Cell Mol Immunol       Date:  2014-10-13       Impact factor: 11.530

2.  Increased circulating Th17 cells after transarterial chemoembolization correlate with improved survival in stage III hepatocellular carcinoma: a prospective study.

Authors:  Yuan Liao; Bo Wang; Zhi-Liang Huang; Ming Shi; Xing-Juan Yu; Limin Zheng; Shengping Li; Lian Li
Journal:  PLoS One       Date:  2013-04-02       Impact factor: 3.240

3.  Expression pattern of tumour-associated antigens in hepatocellular carcinoma: association with immune infiltration and disease progression.

Authors:  J Liang; T Ding; Z-W Guo; X-J Yu; Y-Z Hu; L Zheng; J Xu
Journal:  Br J Cancer       Date:  2013-07-18       Impact factor: 7.640

4.  Immunotherapy of Dual-Function Vector with Both Immunostimulatory and B-Cell Lymphoma 2 (Bcl-2)-Silencing Effects on Gastric Carcinoma.

Authors:  Lanying Ma; Mei Han; Zumureti Keyoumu; Hua Wang; Saifuding Keyoumu
Journal:  Med Sci Monit       Date:  2017-04-25
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.